Nycomed shareholders approve demerger
Shareholders of Norwegian contrast developer Hafslund Nycomedhave approved a plan to demerge the company's energy businessfrom its pharmaceutical unit. Under the plan, the Oslo company'spharmaceutical business will be known as Nycomed ASA, while
Shareholders of Norwegian contrast developer Hafslund Nycomedhave approved a plan to demerge the company's energy businessfrom its pharmaceutical unit. Under the plan, the Oslo company'spharmaceutical business will be known as Nycomed ASA, while theenergy unit will be called Hafslund ASA. Nycomed shares will betraded on the Oslo, London, and Copenhagen exchanges, while NycomedAmerican Depository Receipts will be listed on the New York StockExchange under the symbol "NYD."